Helix Announces the Results of Its Annual General and Special Meeting
19 12월 2013 - 1:07PM
Marketwired
Helix Announces the Results of Its Annual General and Special
Meeting
AURORA, ONTARIO--(Marketwired - Dec 18, 2013) - Helix BioPharma
Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"), a biopharmaceutical
company developing drug candidates for the prevention and treatment
of cancer, announces that its Annual General and Special Meeting
(the "Meeting") was held today as scheduled.
Shareholders approved the election of Yvon Bastien, Slawomir
Majewski, Marek Orlowski, Sven Rohmann, Robert A. Verhagen, Stacy
L. Wills and Slawomir Ludwikowski and as directors at the Meeting.
Based on proxies received prior to the Meeting, more than 99% of
the shares represented by proxy at the Meeting were voted "for"
each of Messrs. Bastien, Majewski, Orlowski, Rohmann, Verhagen and
Wills. However, in the case of Mr. Ludwikowski a majority of the
votes represented by proxy at the Meeting were withheld from voting
and, in accordance with Helix's majority voting policy, Mr.
Ludwikowski is required to submit his resignation to the board of
directors for its consideration.
In addition, BDO Canada LLP, Chartered Accountants, were
appointed as auditors. Shareholders also approved a resolution
re-approving the 2010 Equity Compensation Plan and the granting by
Helix of options, rights and other entitlements under the 2010
Equity Compensation Plan until December 18, 2016, which is three
years from the date of the Meeting.
At a board meeting held after the Meeting, Mr. Verhagen was
appointed as President and Chief Executive Officer and Frank
Michalargias was appointed as Chief Financial Officer. Pending the
selection of a new Chair of the board of directors to replace the
former Chair who resigned shortly before the Meeting, Mr. Verhagen
was appointed Interim Chair of the board of directors for a term
not to exceed 6 months. Following the Meeting Mr. Verhagen said,
"given the strong skill sets brought to the board by the directors
elected during today's meeting, the board wanted the opportunity to
assess the merits of each member before a permanent Chair was
chosen. This temporary measure will provide time to allow the board
to make the best choice for long term stability".
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. Helix is actively
developing innovative products for the prevention and treatment of
cancer based on its proprietary technologies. Helix's product
development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel: (905) 841-2300
Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Helix BioPharma (TSX:HBP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024